theMednetRegister

Rheumatoid Arthritis   

Questions discussed in this category

How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspired by the...
4 Answers available
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
Patient with chronic urticaria and rheumatoid arthritis. What would be the safest biologic option for RA?
1 Answer available
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
2 Answers available
How do you approach managing nausea and GI side effects when initiating methotrexate?
3 Answers available
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?
1 Answer available
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
1 Answer available
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
1 Answer available
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
Patient previously trialed two anti-TNFi and Tocilizumab. Avoiding Rituximab due to positive JC virus testing. 
2 Answers available
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
Patient has had previous failure of methotrexate. Would you switch to alternative (TNFi or Rituximab) or continue abatacept with regular dermatology...
2 Answers available
What is your treatment approach for a young female who has an idiopathic small right elbow effusion with synovial thickening that has resulted in limitation in her range of motion?
1 Answer available
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
1 Answer available
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
Is there any concern for drug interactions of DMARDs and/or biologics with anti seizure medications?
1 Answer available
How do you counsel patients with RA stable on csDMARDs on whether to attempt tapering or not?
While remission rates after lowering or discontinuing therapy are lower, there is still a population of patients who do not require full-dose therapy ...
2 Answers available
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
Which csDMARD do you taper in order, and is there a tapering strategy (duration/dose)?
2 Answers available
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Given the drug-drug interaction, do you monitor more closely for methotrexate toxicity, counsel on symptoms of methotrexate toxicity, or avoid the com...
2 Answers available
Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?
1 Answer available
When do you recommend initiation of targeted therapies in active RA with history of malignancy?
What is your most and least preferred? In case of cancer in remission and in case of non-remission?
1 Answer available
Do you combine methotrexate and leflunomide for the treatment of RA?
3 Answers available
What is the maximum dose of leucovorin that you use with methotrexate?
2 Answers available
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
How do you counsel patients in this scenario? 
1 Answer available
Is there a role for the use of transient elastography (FibroScan) to monitor liver fibrosis in patients on long term methotrexate?
3 Answers available
What is your approach for cancer screening for elderly onset RA?
1 Answer available
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
2 Answers available
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
Arthritis did not respond to HCQ.
2 Answers available
Would you escalate therapy in a patient with rheumatoid arthritis without synovitis, but a new rheumatoid nodule?
Do you consider the appearance of a new rheumatoid nodule as a sign of RA activity?
1 Answer available
What is your approach to work up for patients referred for early onset osteoarthritis?
1 Answer available
Would you uptitrate methotrexate dosing when a patient flares on a TNFi and methotrexate 15 mg weekly?
2 Answers available
When would you consider utilizing bone scintigraphy in the assessment of inflammatory arthritis?
2 Answers available
Do you use the peri-operative management of biologics and DMARDs guidelines, which were mainly based on total hip and knee replacement surgeries, for all peri-operative surgical management?
Are there certain surgeries (including orthopedic) that you recommend continuing biologic DMARDs? 
1 Answer available
How do you approach restarting cDMARDS/bDMARDS in a patient with active RA after incidence of disseminated CNS VZV infection while on tofacitinib?
1 Answer available
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
Does your choice of DMARD/biologics change due to increased risk of malignancy?
1 Answer available
Do you consider Anti-carbamylated protein antibodies (anti-CarP) as having any significance in evaluation of patients if RF and ACPA negative and clinically no active synovitis yet widespread arthralgias and generalized osteoarthritis?
1 Answer available
Do you offer LDRT for psoriatic arthritis, rheumatoid arthritis, or polymyalgia rheumatica or fibromyalgia?
2 Answers available
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
2 Answers available
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
1 Answer available
How do you approach patients referred for C1-2 pannus/erosions without clinical findings or serologies consistent with RA or CPPD arthropathy?
3 Answers available
How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?
1 Answer available
How do you approach selecting biologic therapy vs non-biologic DMARD (such as methotrexate) as initial therapy in patients with new RA diagnosis with significant erosive disease?
This question is part of a collaboration with RheumMadness and is specifically in reference to: NORD-STAR (Østergaard et al., PMID 3742364...
5 Answers available
How do you counsel patients who prefer to continue TNFi therapy indefinitely for rheumatoid arthritis despite long-standing remission?
Do you advocate to taper the TNF-i or simply continue to monitor for long term adverse events? This question is part of a collaboration with Rheu...
3 Answers available
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
1 Answer available
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
1 Answer available
How do you approach the timing of DMARD initiation in patients with active RA who are on treatment for latent TB?
Is it different between DMARDs (csDMARDs, biologic DMARDs, and target synthetic DMARDs)?
1 Answer available
Do you consider new onset autoimmune disease (e.g. seronegative rheumatoid arthritis) a few months after completing immunotherapy for cancer to be an immune-related adverse effect to the immunotherapy?
1 Answer available
Can JAK inhibitors for established rheumatoid arthritis be continued when starting an immune checkpoint inhibitor?
2 Answers available
What is your approach to leflunomide and statin use in RA patients?
 Is the interaction considered severe?
2 Answers available
Would you continue Jak inhibitor therapy in a patient with long standing, previously refractory RA in their 60s who was found to have stenosis of the left common femoral artery and no other history of arteriosclerotic disease?
1 Answer available
Would you consider the use of doxycycline or minocycline in the management of RA?
4 Answers available
How do you approach an obese patient on long-term methotrexate with normal liver tests in terms of workup for underlying fatty liver?
Would you start with a baseline ultrasound and then pursue further workup such as fibroscan if fatty liver is present, or other?
1 Answer available
Would you consider adding dupilumab to adalimumab (or other monoclonal antibodies) in a patient who has RA and refractory atopic dermatitis and already is on MTX 25 mg weekly?
2 Answers available
How would you approach rheumatoid arthritis treatment for widespread large rheumatoid nodules but no active synovitis or subjective joint pain?
Patient taken off methotrexate.
2 Answers available
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
2 Answers available
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
1 Answer available
In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?
1 Answer available
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
Assuming no symptoms of TB, should patients be treated for latent TB prior to starting TNF inhibitors or other immunosuppressive agents?
1 Answer available
Do you prefer to taper rituximab by extending the interval between doses or decreasing the actual dose administered for RA patients who have achieved longstanding remission?
3 Answers available
How would you approach treating a patient with Rheumatoid arthritis/Psoriatic arthritis and alcoholic cirrhosis?
1 Answer available
What would be your approach to a patient with new diagnosis of seropositive rheumatoid arthritis manifesting as a constrictive pericarditis with no joint pain complaints?
Would you begin with DMARD therapy like MTX or would you consider starting with an IL-1 antagonist such as Acralyst?
1 Answer available
What are best practices in management of severe acute infusion reaction from infliximab?
Patient became acutely flushed, developed severe and prolonged hypotension with brief loss of consciousness, dizziness, nausea, dry heaves and headach...
1 Answer available
Have you seen rheumatoid nodules or RA-ILD in patients with seronegative RA?
While classically described as seen in seropositive patients, have they been reported in seronegative RA?
2 Answers available
Would you consider utilizing a TNF-inhibitor in a patient with RA/SLE overlap who has already tried methotrexate, hydroxychloroquine, and abatacept?
Female patient in her 20's with RA/SLE has been on steroids and methotrexate, currently on HCQ and Orencia. Failing Orencia with active disease. Want ...
4 Answers available
What is your initial treatment of choice in patients with RA and associated interstitial lung disease?
1 Answer available
How would you treat active rheumatoid arthritis in a patient in complete response on loralatinib for stage IV ALK positive NSCLC?
Patient already on methotrexate and plaquenil.   
1 Answer available
How would you approach the use of JAK inhibitors in a patient with stable RA who is now starting treatment for pulmonary MAC infection?
Patient previously failed abatacept and Rituximab.
1 Answer available
Would you have a patient temporarily discontinue methotrexate while receiving a FAST or FAST FORWARD regimen for breast irradiation?
The patient is on a dose of 22 mg of methotrexate weekly for severe rheumatoid arthritis. If you would discontinue the methotrexate, how long would y...
1 Answer available
How do you approach methotrexate management around vaccines other than COVID and influenza?
Data is clear that we should hold methotrexate at least one week after COVID and flu vaccines. How do you approach methotrexate management around Shin...
1 Answer available
How often do you monitor labs in patients taking methotrexate?
4 Answers available
Have you used jak inhibitors with TNF blockade at the same time?
1 Answer available
How do you manage injection site reactions in patients on subcutaneous biologics such as TNF inhibitors?
In what cases do you discontinue the medication?
2 Answers available
In an RA patient with positive RF and CCP abs who is stable on TNFi biologic, how would you approach incidentally found low titer positive DsDNA abs?
Would you switch to a non TNFi biologic or continue current regimen with careful monitoring for evolution of lupus manifestations?
2 Answers available
What is your treatment approach for patients with MDA5-positive amyopathic dermatomyositis, who also have anti-CCP positive rheumatoid arthritis but no clinical lung involvement?
1 Answer available
What target do you utilize in clinical practice for defining disease remission in RA?
This question is part of a collaboration with RheumMadness and is specifically in reference to:BeSt TrialMeasurement of Patient Outcomes in Arthritis
1 Answer available
What is your approach to patients with positive anti-CCP, negative RF and tobacco use, but no current signs of active rheumatoid arthritis?
1 Answer available
Is there utility of modifying DMARD treatment in a seropositive rheumatoid arthritis patient with recurrent pleural effusions and RA nodules without other signs of active disease?
2 Answers available
Do you continue to utilize ESR and CRP in patients on tocilizumab?
2 Answers available
What is the preferred approach to treating poorly-controlled RA in the setting of active hepatitis B undergoing anti-viral therapy?
1 Answer available
How would you manage scleritis perforans in a patient with seropositive rheumatoid arthritis/scleroderma overlap?
Patient has failed methotrexate and adalimumab. 
2 Answers available
How do you approach oral DMARD and/or biologic selection in patients with RA and a history of gastric bypass or whom are planning bariatric surgery?
1 Answer available
Should we be using heart rate variability counts to gauge disease activity in persons with rheumatoid arthritis?
Studies are now being pursued to ability the of implantable bioelectric device stimulation of the vagal nerve to attenuate disease activity in patient...
2 Answers available
How would you approach treating a patient with active rheumatoid arthritis and a history of treated lymphoma that is currently in remission?
Given the controversy in the literature regarding TNFi or MTX associated lymphoma in patients with RA.
1 Answer available
What is your approach to managing RA patients with history of organ transplant already on immunosuppressive therapy such as cyclosporine or cellcept?
4 Answers available
How do you approach methotrexate management in patients with rheumatoid arthritis and moderate NASH but no fibrosis per FibroSURE?
Continue MTX with monitoring of LFTs vs switching to another oral DMARD (aza, lef) vs GI for fibroscan?
1 Answer available
How would you approach the treatment of erosive inflammatory arthritis (RA or SpA) in a patient with multiple sclerosis on ocrelizumab who has failed csDMARD therapy?
2 Answers available
Do you ever consider using a higher dose of upadacitinib (30 mg daily) for rheumatoid arthritis in patients who fail to respond/partially respond to established dosing of 15 mg daily? 
1 Answer available
How do you approach treatment of RA with methotrexate in a patient with treated Hepatitis C and normal liver function?
1 Answer available
What bDMARD would you choose for a patient with RA with high infection risk and inadequate response to cDMARDs?
Infection risk being primarily chronic venous stasis ulcers
1 Answer available
What is your approach to discussing risk of adverse cardiovascular events in patients with RA whom you are considering starting a JAK inhibitor?
Data is mixed based on the results of ORAL surveillance, STAR-RA and nationwide cohort studies.
2 Answers available
How do you approach tapering off JAK inhibitors in patients with rheumatoid arthritis who are in sustained remission?
3 Answers available
How do you weigh the risks of re-treatment with infliximab in a patient who has been off it for over a year?
2 Answers available
How do you approach RA management in a patient who develops a new solid tumor while on therapy?
2 Answers available
When do you consider referral to hand surgery for management of joint deformity in RA?
2 Answers available
What is your approach in a patient who develops interstitial lung disease while on anti-TNF therapy?
Do you change therapy? If they are also on methotrexate, which medication would you potentially stop first?
1 Answer available
Do you counsel your RA patients to hold their methotrexate dose for simple infections such as UTIs?
1 Answer available
What is the role of synovectomy in the diagnosis and management of patients with inflammatory arthritis?
1 Answer available
Would you have concerns starting an anti-TNF in RA patients with history of ITP/chronic idiopathic thrombocytopenia?
1 Answer available
How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?
Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is cons...
2 Answers available
What role do you see for JAK inhibitors in RA treatment strategies given the data we now have regarding CV and cancer outcomes?
For example, would it be appropriate to consider JAK inhibitor therapy as preferable to TNF-alpha inhibitor in patients with heart failure with reduce...
4 Answers available
Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?
2 Answers available
Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?
2 Answers available
How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?
2 Answers available
How would you approach treating patients with RA refractory to cDMARDs and a prior history of MALT lymphoma?
1 Answer available
How do you approach DMARD therapy in patients with rheumatoid arthritis and chronic hepatitis B?
Hepatitis screening labs revealing Hep B ag and core positivity with positive PCR
2 Answers available
Is active rheumatoid arthritis (RA) a contraindication to hypofractionated breast irradiation?
How does a diagnosis of active RA inform your treatment approach for patients with breast cancer, if at all? 
4 Answers available
Would you start a TNF-I for seronegative non-erosive RA in a patient with positive ANA and sun sensitivity without other SLE features?
1 Answer available
Do you avoid dupilumab (IL-4 inhibition) for severe asthma in patients already taking a biologic agent for RA?
1 Answer available
What is your approach to a patient with well-controlled seropositive RA on abatacept who develops melanoma?
Would you change the treatment to rituxan or continue orencia with regular dermatology follow up?
1 Answer available
Would you have any concerns about starting an anti-TNF in RF and anti-CCP positive RA patients who also have high titer ANA?
Is there an increased drug induced lupus risk?
2 Answers available
How would you treat corneal melt (in the absence of peripheral arthritis) in rheumatoid arthritis?
What immunosuppression and dosing do you typically use?
1 Answer available
Do you find 14.3.3 eta or vectra DA helpful in clinical practice?
1 Answer available
How would you approach treatment for fulminant RA-associated ILD?
Would you discontinue Methotrexate and TNF inhibitors even if previously no side effects from these medications, and would you consider Cyclophosphami...
1 Answer available
What immunosuppressive agents would be available to patients with a history of melanoma?
Would you use immunosuppression in patients several years after curative treatment for melanoma?
1 Answer available
How would you approach definitive treatment of intermediate-risk prostate cancer with baseline severe (AUA >25) urinary dysfunction and severe rheumatoid arthritis?
Would your answer change for favorable vs unfavorable intermediate risk disease?
1 Answer available
Do you routinely obtain a chest x-ray prior to initiating anti-TNF or other biologic therapy?
Does Quantiferon gold replace the need for baseline chest x-ray screen? 
1 Answer available
What was the rationale for abrupt discontinuation of etanercept rather than gradual tapering in the SEAM-RA trial?
The ACR 2021 RA Guidelines suggest the gradual tapering approach is preferable.
2 Answers available
Was the methotrexate dose reduced over time in the combination therapy or methotrexate monotherapy groups in the SEAM-RA trial?
Giving "rescue therapy" to patients in the combination group implies that there is room to escalate to the dose at enrollment. 
1 Answer available
Are the results of the SEAM-RA trial generalizable to other TNF inhibitors given the differences in immunogenicity?
Withdrawal of methotrexate may lead to more disease flares and lack of recoverability with other TNF inhibitors.
1 Answer available
Were the patients enrolled in the SEAM-RA trial prior methotrexate monotherapy non-responders?
Usual clinical practice is to add TNFi once methotrexate monotherapy has failed. If this is the case in these patients, it would seem to increase the ...
1 Answer available
How would you treat a poorly controlled seronegative RA patient who is steroid dependent and is on azathioprine for autoimmune hepatitis?
2 Answers available
How long would you treat with antimycobacterials before starting biologic DMARD in a patient with latent TB and active rheumatoid arthritis?
1 Answer available
What is your approach to a patient with rheumatoid arthritis and moderate disease activity on 25 mg of PO methotrexate?
Do you switch to SQ MTX, or is it best to add tx, such as a TNFi?
1 Answer available
What is your approach to monitoring lipids in patients with rheumatic diseases such as RA and SLE and do you have a lower threshold to start lipid lowering agents compared to the general population?
2 Answers available
What are your thoughts on use of 14-3-3 serum levels in rheumatoid arthritis in conjunction with RF and ACPA?
1 Answer available
What is your methotrexate initiation strategy in DMARD-naive RA patients?
Specifically: starting dose, rapidity of up-titration, frequency of lab monitoring, frequency of office visits, and timing of assessment for treatment...
2 Answers available
What immunosuppressive agents aside from steroids would you use to treat bronchiolitis obliterans in a patient with long-standing seropositive RA?
1 Answer available
What is your approach to a patient with an isolated positive rheumatoid factor, negative anti-CCP antibody, and no clinical or imaging evidence of rheumatoid arthritis?
3 Answers available
How would you manage an active rheumatoid arthritis patient on suppressive antibiotic therapy for ocular HSV who has abnormal liver function tests?
1 Answer available
How do you counsel patients on JAK inhibitors about the risk of venous thromboembolism, MACE, and cancer?
1 Answer available
Do you recommend checking anti-drug antibodies for patients on TNF inhibitors?
If so, how would positive levels guide your management?
3 Answers available
How would you recommend dosing the MMR or other live vaccines for patients with rheumatoid arthritis on immunosuppressive medications such as anti-TNF alpha therapy?
For example, healthcare workers who require these vaccines for employment
1 Answer available
How do you treat RA in patients with pulmonary mycobacterium avium complex (MAC) infections?
1 Answer available
Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?
1 Answer available
Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?
1 Answer available
How would you manage methotrexate therapy in an active rheumatoid arthritis patient undergoing treatment for latent TB with rifampin?
Do you stop methotrexate or adjust the dose? 
1 Answer available
How do you approach treatment of rheumatoid arthritis in a patient with an active hematologic malignancy (such as leukemia or lymphoma) after methotrexate failure?
Does your management change if there is renal involvement of the malignancy? 
2 Answers available
When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?
1 Answer available
Do you switch to certolizumab in RA patients who are doing well on other TNFis and planning to become pregnant?
1 Answer available
What is the biologic of choice in a patient with RA and myasthenia gravis?
1 Answer available
How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?
1 Answer available
Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?
5 Answers available
Is a comprehensive physical exam with vital signs warranted for routine follow-up visits in well-controlled uncomplicated RA patients?
Reduced requirements for documentation by CMS in 2021 with respect to billing and coding have raised new questions about what aspects of physician exa...
1 Answer available
Should MTX be avoided in RA patients with asymptomatic lung nodules?
If so, what would be an ideal DMARD in this setting?
1 Answer available
How do you approach patients with overlapping features of PMR and seronegative RA?
1 Answer available
What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?
2 Answers available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available
Is it appropriate to consider biologic therapy for treatment of RA in a patient with non-small cell lung carcinoma treated with radiation therapy, who has ongoing active synovitis uncontrolled by conventional DMARDs?
1 Answer available
How does the presence of nonalcoholic fatty liver disease (NAFLD) impact your choice of csDMARD for RA?
1 Answer available
What is the safest approach to treating refractory RA in the setting of an active solid organ malignancy?
Prior therapies include MTX, abatacept, rituximab
1 Answer available
Do you use leflunomide in rheumatoid arthritis patients on hemodialysis?
If so, would you adjust the dose?
1 Answer available
What is your inflammatory arthritis differential when a patient presents with unilateral TMJ synovitis?
2 Answers available
Should JAK inhibitors and anti-IL6 medications be avoided in patients with known diverticulosis?
2 Answers available
Should tuberculosis screening be performed before beginning methotrexate for treatment of rheumatoid arthritis?
1 Answer available
Is there a role for the VECTRA or other multi-biomarker tests in evaluating rheumatoid arthritis disease activity?
1 Answer available
What is your approach to dental prophylaxis for patients on biologics?
1 Answer available
Should methotrexate be categorically avoided in RA patients with COPD or RA-ILD?
1 Answer available
What is your work up and management for patients who develop neuropathy on a TNF inhibitor?
1 Answer available
Do you have any suggestions about how to improve rheumatology training in internal medicine residency programs?
Due to the shortage of rheumatologists, primary care physicians may need to manage some rheumatologic issues.
1 Answer available
How do you manage patients who are Hepatitis B core antibody positive/surface antigen negative and starting a biologic DMARD (other than rituximab)?
1 Answer available
Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?
1 Answer available
Are subcutaneous RA therapies less effective in obese patients?
1 Answer available
Do you use precision medicine tools (such as RNA testing, PRISM-RA) in clinical practice before starting a TNF inhibitor for RA?
https://www.prismra.com
2 Answers available
How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?
This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet
1 Answer available
What baseline work-up do you do for patients with suspected palindromic rheumatism?
1 Answer available
Would you re-challenge patients who have had a TNF-associated paradoxical adverse event (such as inflammatory bowel disease) with a different TNF inhibitor?
1 Answer available
Is there a role for ultrasound in assessing for "clinically silent" inflammatory arthritis prior to tapering DMARD therapy?
1 Answer available


Papers discussed in this category

Journal of psoriasis and psoriatic arthritis, 2019-04
TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.
Arthritis Rheumatol, 2016 Jan
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Clin. Rheumatol., 2017 Aug 18
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
Archives of internal medicine, 2008-09-22
Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.
Arthritis and rheumatism, 2010-06
Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.
Arthritis care & research, 2012-05
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Eur J Rheumatol, 2017 Feb 23
Management of the temporomandibular joint in inflammatory arthritis: Involvement of surgical procedures.
Rev Bras Reumatol Engl Ed, 2016 Mar 16
What rheumatologists should know about orofacial manifestations of autoimmune rheumatic diseases.
Arthritis & rheumatology (Hoboken, N.J.), 2016-11
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Annals of the rheumatic diseases, 2019-04
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Southern medical journal, 2016-11
Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.
Annals of the rheumatic diseases, 2011-05
Lupus Atherosclerosis Prevention Study (LAPS).
Atherosclerosis, 2015 Aug 28
Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
Clin Rheumatol, 2012 Nov 22
Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Ann Pharmacother,
Effect of hemodialysis on leflunomide plasma concentrations.
Arthritis Care Res (Hoboken), 2016 Jan
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Rheumatol Int, 2020 Sep 18
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
N Engl J Med,
Clinical practice. Care of the asplenic patient.
Mediterr J Rheumatol, 2020 Jun 11
Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies.
J Rheumatol, 2014 Aug 15
Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.
Ann Clin Lab Sci,
Serum 14-3-3η Could Improve the Diagnostic Rate of Rheumatoid Arthritis and Correlates to Disease Activity.
Pediatr Rheumatol Online J, 2021 Feb 16
Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis.
Clin Rheumatol, 2020 Mar 23
Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren's syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis.
Ann Rheum Dis, 2019 Aug 14
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
Arthritis Rheumatol, 2021 Mar 24
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.
Arthritis Rheum,
Tuberculosis associated with therapy against tumor necrosis factor alpha.
JAMA Netw Open, 2021 Feb 01
Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease.
Rheumatology (Oxford),
Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.
Arthritis and rheumatism, 1992-08
Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.
Arthritis and rheumatism, 1995-12
Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment.
Arthritis care & research, 2019-11
Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis.
Arthritis Care Res (Hoboken), 2019 Dec
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.
Int J Rheum Dis, 2020 Sep 10
Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis.
J Rheumatol, 2015 Jul 15
14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.
Lancet,
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Arthritis & rheumatology (Hoboken, N.J.), 2016-01
Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Ann Intern Med, 2020 Sep 22
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.
Ann Rheum Dis, 2021 May 28
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
RMD Open,
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.
Arthritis Care Res (Hoboken), 2019 Nov 29
Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
Semin Arthritis Rheum, 2008 Dec 31
The risk of infections with biologic therapies for rheumatoid arthritis.
Ann Intern Med, 2021 Aug 31
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Lancet Oncol., 2013-10-01
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Arthritis Care Res (Hoboken), 2021 Jul
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Clin Liver Dis (Hoboken), 2018 Aug 22
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.
Ann Rheum Dis, 2016 Oct 03
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Arthritis Rheumatol, 2021 Mar 24
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
BMJ Open, 2014 Aug 14
Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
Int J Rheum Dis, 2018 Sep 05
Long-term patient reported outcomes of elbow, wrist and hand surgery for rheumatoid arthritis.
N Engl J Med, 2003 Feb 13
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Metabolites, 2022 Nov 05
Nonalcoholic Fatty Liver Disease-A Concise Review of Noninvasive Tests and Biomarkers.
J Rheumatol, 2022 Mar 15
Using FibroScan to Assess for the Development of Liver Fibrosis in Patients With Arthritis on Methotrexate: A Single-center Experience.
Semin Arthritis Rheum, 2020 Jul 02
Recurrent rheumatoid arthritis following allogeneic bone marrow transplant and seronegativity induced by rituximab therapy.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019-08
Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Transpl Int, 2022 Aug 12
Abatacept Rescue Therapy in Kidney Transplant Recipients: A Case Series of Five Patients.
Immunity, 2017-06-20
Mechanisms and Therapeutic Relevance of Neuro-immune Communication.
Autonomic neuroscience : basic & clinical, 2008-12-05
Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis.
Drug Dev Res, 2014 Nov
Cardiovascular risk in psoriatic patients detected by heart rate variability (HRV) analysis.
Thorax, 1985 May
Thoracoscopic, histological, and clinical findings in nine case of rheumatoid pleural effusion.
BMJ, 2023 May 30
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.
BMJ, 2023 May 30
Monitoring methotrexate toxicity: Are we being over-vigilant?
Ann Rheum Dis, 2021 Sep 07
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Arthritis research & therapy, 2023 Nov 20
Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.
Arthritis research & therapy, 2021 Jul 08
Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon.
Journal for immunotherapy of cancer, 2022 Jan
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.
Clinical rheumatology, 2020 Sep 28
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
Frontiers in immunology, 2022 Sep 15
Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib.
Cancer cell, 2022 May 09
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Nature communications, 2021 Jun 07
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Lancet (London, England), 2023 Feb 24
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Lancet (London, England), 2023 Feb 24
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
The American journal of gastroenterology, 2003 Jun
The incidence and management of infusion reactions to infliximab: a large center experience.
The Journal of rheumatology, 2015 Jun 15
Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.
Medicine, 2014 Oct
Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis.
Rheumatology (Oxford, England), 2011-12
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
RMD open, 2022 Nov
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
British journal of rheumatology, 1992 Nov
Injection therapy of superficial rheumatoid nodules.
Pharmacotherapy, 2002-09
A review of methotrexate-induced accelerated nodulosis.
Medicine, 2001 Jul
The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis.
American journal of respiratory and critical care medicine, 2015 Jul 15
Methotrexate-induced Accelerated Pulmonary Nodulosis.
Ann Rheum Dis, 2022 Jan 13
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
J Immunother Cancer, 2023 Mar
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Diagnostics (Basel, Switzerland), 2022 Jul 08
Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis.
BMC public health, 2008 Jan 21
The SMILE study: a study of medical information and lifestyles in Eindhoven, the rationale and contents of a large prospective dynamic cohort study.
Rheumatology (Oxford, England), 2021 Nov 03
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).
Arthritis & rheumatology (Hoboken, N.J.), 2017-03
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Annals of the rheumatic diseases, 2019 Jul 30
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Autoimmunity reviews, 2021 Apr 19
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Rheumatology (Oxford, England), 2021 Dec 24
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
The Lancet. Rheumatology, 2024 Apr 04
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Rheumatology (Oxford, England), 2023 Oct 19
A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
JAMA, 2021 May 04
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Annals of the rheumatic diseases, 2016 Jul 12
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
PloS one, 2014
IL-6 stimulates intestinal epithelial proliferation and repair after injury.
Arthritis care & research, 2017-12
Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.
Annals of internal medicine, 2019-06-18
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
Arthritis care & research, 2022 Jun 19
2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Clin Rheumatol, 2021 Apr
Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis.
The Journal of rheumatology, 1997 May
Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis.
British journal of rheumatology, 1995 May
Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients.
Annals of the rheumatic diseases, 2016-04
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Arthritis research & therapy, 2021 Sep 18
HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
Arthritis and rheumatism, 1988-07
The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients.
Arthritis and rheumatism, 1993-06
Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial.
The Journal of rheumatology, 2014 Apr 15
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
JAMA internal medicine, 2017 Nov 01
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Annals of the rheumatic diseases, 2024 Jan 11
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
Rheumatol Int, 2021 Jan 29
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.
The Journal of dermatological treatment, 2018 Sep 25
Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.